Examining “value” in the management of prostate cancer

Three new articles in the Journal of Oncology Practice take close look at the issue of risk/benefit and “value” in the management of prostate cancer today — and the management of advanced disease in particular. … READ MORE …

Metabolic aberrations and risk for prostate cancer

According to a newly published study of data from > 285,000 European males (the Metabolic Syndrome and Cancer Project), men with metabolic aberrations are at slightly less risk for a diagnosis of prostate cancer compared with men who have normal levels of metabolic factors … but their risk for prostate cancer-specific mortality is similar. … READ MORE …

Managing metabolic syndrome in men at risk for progressive prostate cancer

Over a month ago we reported on a paper by Häggström et al. that noted an increased risk of death among patients with prostate cancer and metabolic syndrome. … READ MORE …

Metabolic syndrome and risk for prostate cancer-specific mortality

According to an article due to be published on line today in Cancer,  a group of clinical characteristics commonly referred to as “metabolic syndrome” are strongly associated with an increased risk for prostate cancer-specific mortality among men diagnosed with prostate cancer, but are not associated with an increased risk for the initial diagnosis. … READ MORE …

FDA formalizes warning of cardiovascular risks for LHRH agonists

According to a media release from the U.S. Food and Drug Administration (FDA) yesterday, the agency has asked manufacturers of the class of drugs known as luteinizing hormone-releasing hormone (LHRH) or gonadotropin-releasing hormone (GnRH) agonists to include warnings about risk for cardiovascular disease and diabetes in product labeling for these drugs. … READ MORE …

US FDA reviewing the safety of LHRH agonists

For many years it has been understood by specialists that hormonal treatment of prostate cancer patients with luteinizing hormone releasing hormone (LHRH) agonists — also known as gonadatropin releasing hormone or GnRH agonists — is associated with metabolic side effects that include risks for cardiovascular disease and diabetes. … READ MORE …

“Metabolic” therapies for treatment and prevention of cancer

For those who may have been tempted by some of the more extreme forms of “metabolic” or “nutritional” therapies as a means to treat or prevent prostate cancer, we recommend reading a brief (and patient friendly) article in this month’s issue of Oncology. … READ MORE …